Log in

Relevant bibliographies by topics / Dalfampridine

Contents

Journal articles

Academic literature on the topic 'Dalfampridine'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dalfampridine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dalfampridine"

1

Satchidanand, Nikhil, Allison Drake, A. Smerbeck, et al. "Dalfampridine benefits ambulation but not cognition in multiple sclerosis." Multiple Sclerosis Journal 26, no. 1 (2018): 91–98. http://dx.doi.org/10.1177/1352458518815795.

Full text

Abstract:

Background: Impaired cognition and ambulation are common in multiple sclerosis (MS). Dalfampridine is the first Food and Drug Administration (FDA)–approved medication to treat impaired ambulation in MS. Dalfampridine may benefit patients with cognitive impairment, given its effects on saltatory conduction and the association between cognitive and motor function. Objective: To examine the effects of dalfampridine on cognition in MS. To determine if the anticipated improved cognition is grounded in dalfampridine’s effects on ambulation. Methods: Adults with MS were randomized to dalfampridine (

APA, Harvard, Vancouver, ISO, and other styles

2

Farag, Amanda, and Allison Averill. "Dalfampridine." American Journal of Physical Medicine & Rehabilitation 92, no. 7 (2013): 635–36. http://dx.doi.org/10.1097/phm.0b013e31826ed8ea.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yapundich, Robert, Angela Applebee, Francois Bethoux, et al. "Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis." International Journal of MS Care 17, no. 3 (2015): 138–45. http://dx.doi.org/10.7224/1537-2073.2014-040.

Full text

Abstract:

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-daily dalfampridine-ER tablets, 5 mg (n = 144) or 10 mg (n = 143), or placebo (n = 143) for 4 weeks. Primary efficacy endpoint was change from baseline walking speed by the Timed 25-Foot Walk 3 to 4 hours after the last dose. At 40% of sites, 2-week change from baseline walking distance was measured

APA, Harvard, Vancouver, ISO, and other styles

4

Goodman, Andrew D., Francois Bethoux, Theodore R. Brown, et al. "Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials." Multiple Sclerosis Journal 21, no. 10 (2015): 1322–31. http://dx.doi.org/10.1177/1352458514563591.

Full text

Abstract:

Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking speed relative to placebo in patients with multiple sclerosis (MS). Objectives: Evaluation of long-term safety and efficacy of dalfampridine-ER in open-label extensions (MS-F203EXT, MS-F204EXT). Methods: Patients received dalfampridine-ER 10 mg twice daily; and had Timed 25-Foot Walk (T25FW) assessments at 2, 14 and 26 weeks, and then every 6 mont

APA, Harvard, Vancouver, ISO, and other styles

5

Cameron, Michelle H., Mary Fitzpatrick, Shannon Overs, Charles Murchison, Jane Manning, and Ruth Whitham. "Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study." Multiple Sclerosis Journal 20, no. 6 (2013): 733–38. http://dx.doi.org/10.1177/1352458513507356.

Full text

Abstract:

Background: In short-term trials, dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS). The tolerability and effects of dalfampridine-ER in clinical practice have not been reported. Objectives: The objective of this paper is to determine the clinical tolerability and effects of dalfampridine on walking and community participation. Methods: All patients at the Portland VA Medical Center prescribed dalfampridine-ER over one year completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Timed Walk (2MTW), and Communi

APA, Harvard, Vancouver, ISO, and other styles

6

Fjeldstad, Cecilie, Gustavo Suárez, Michael Klingler, Herbert R. Henney, Adrian L. Rabinowicz, and Gabriel Pardo. "Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis." International Journal of MS Care 17, no. 6 (2015): 275–83. http://dx.doi.org/10.7224/1537-2073.2014-036.

Full text

Abstract:

Background: Dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS), as demonstrated by walking speed improvement. This exploratory study evaluated treatment effects of dalfampridine-ER on gait, balance, and walking through treatment withdrawal and reinitiation. Methods: Dalfampridine-ER responders, based on Timed 25-Foot Walk (T25FW) assessment before study entry, were included in this open-label, three-period, single-center study. Period 1: on-drug evaluations performed at screening and 1 week after screening. Period 2: dalfampridine-ER withdrawal and off-

APA, Harvard, Vancouver, ISO, and other styles

7

Plummer, Prudence. "Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis." International Journal of MS Care 18, no. 3 (2016): 105–15. http://dx.doi.org/10.7224/1537-2073.2014-114.

Full text

Abstract:

Background: Research has not yet compared the treatment effects of dalfampridine with traditional rehabilitation of gait impairments in multiple sclerosis (MS). The purpose of this review was to critically appraise the evidence for dalfampridine and gait training for increasing gait speed in people with MS. Methods: A systematic search of the research literature was conducted. Consideration was given to only randomized controlled trials (RCTs), systematic reviews, and meta-analyses. For selection of gait training studies, only studies involving task-specific gait training interventions and mea

APA, Harvard, Vancouver, ISO, and other styles

8

De Giglio, Laura, Francesca De Luca, Flavia Gurreri, et al. "Effect of dalfampridine on information processing speed impairment in multiple sclerosis." Neurology 93, no. 8 (2019): e733-e746. http://dx.doi.org/10.1212/wnl.0000000000007970.

Full text

Abstract:

ObjectiveTo test a possible benefit of dalfampridine on information processing speed (IPS), a key function for cognitive impairment (CogIm) in multiple sclerosis (MS).MethodsIn this randomized, double-blind, placebo-controlled trial, we included patients with a score on the Symbol Digit Modalities Test (SDMT) under the 10th percentile of the reference value. Patients were randomized in a 2:1 ratio to receive dalfampridine 10 mg or placebo twice daily for 12 weeks. They underwent a comprehensive neuropsychological evaluation at screening (T0), at the end of treatment (T1), and after a 4-week fo

APA, Harvard, Vancouver, ISO, and other styles

9

Klineova, Sylvia, Rebecca Farber, Joshua Friedman, Colleen Farrell, Fred D. Lublin, and Stephen Krieger. "Objective and subjective measures of dalfampridine efficacy in clinical practice." Multiple Sclerosis Journal - Experimental, Translational and Clinical 4, no. 3 (2018): 205521731878674. http://dx.doi.org/10.1177/2055217318786742.

Full text

Abstract:

Background Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patient-reported ambulation inventory. Methods Chart review identified patients with multiple sclerosis for whom dalfampridine was prescribed. T25FW data were extracted from medical records. Participants completed a dalfampridine-specific version of the multiple sclerosis walking scale (dMSWS-12) to asses

APA, Harvard, Vancouver, ISO, and other styles

10

Chwieduk, Claudine M., and Gillian M. Keating. "Dalfampridine Extended Release." CNS Drugs 24, no. 10 (2010): 883–91. http://dx.doi.org/10.2165/11205910-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!